PMID- 31202832
OWN - NLM
STAT- MEDLINE
DCOM- 20200214
LR  - 20200214
IS  - 1096-0007 (Electronic)
IS  - 0014-4835 (Linking)
VI  - 185
DP  - 2019 Aug
TI  - Traditional two-dimensional mesenchymal stem cells (MSCs) are better than 
      spheroid MSCs on promoting retinal ganglion cells survival and axon regeneration.
PG  - 107699
LID - S0014-4835(18)30929-1 [pii]
LID - 10.1016/j.exer.2019.107699 [doi]
AB  - The loss of retinal ganglion cells (RGCs) is one of the common pathological 
      features associated with optic nerve diseases leading to blindness. The aims of 
      our study were to compare the neuroprotection of two forms of human umbilical 
      cord blood-derived mesenchymal stem cells (hUCB-MSCs) on RGCs and axon 
      regeneration after optic nerve crush (ONC) in vivo, and to investigate the 
      molecular mechanism. The effects of intravitreally transplanted hUCB-MSCs 
      cultured in two-dimensional (2D-MSCs) and spheroids (3D-MSCs) were assessed by 
      the survival of RGCs, regenerating axons, and flash visual evoked potentials 
      (fVEP); the level of signal factors secreted by transplanted MSCs in vitreous and 
      the marker protein levels of JAK/STAT3, PI3K/Akt/mTOR and MAPK/ERK pathways were 
      detected using Bead-Based analysis and Western blot, respectively. We found that 
      RGCs began to lose at day 3 after ONC, rapidly decreased at day 7, and flattened 
      at day 14. The neuroprotection of transplanted 2D-MSCs was much stronger than 
      that of 3D-MSCs. The transplanted 2D-MSCs could survive at least 2 weeks without 
      differentiation and keep the characters of MSCs, which secreted multiple tropic 
      factors and accompanied by activation of JAK/STAT3 and MAPK/ERK signaling 
      pathways, top three most abundant factors: stem cell growth factor- beta (SCGF-beta), 
      hepatocyte growth factor (HGF), and monocyte chemoattractant protein-1 (MCP-1). 
      These results indicate that intravitreal injection of 2D-MSCs is a promising 
      therapeutic strategy for retinal pathological diseases characterized by the loss 
      of RGCs and open the door for the application of SCGF-beta, HGF, and MCP-1 in the 
      treatment of optic nerve diseases.
CI  - Copyright (c) 2019. Published by Elsevier Ltd.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Ophthalmology, The 2nd Xiangya Hospital, Central South University, 
      Changsha, Hunan, 410011, China; Hunan Clinical Research Center of Ophthalmic 
      Disease, Changsha, Hunan, 410011, China.
FAU - Wang, Cong
AU  - Wang C
AD  - Department of Ophthalmology, The 2nd Xiangya Hospital, Central South University, 
      Changsha, Hunan, 410011, China; Hunan Clinical Research Center of Ophthalmic 
      Disease, Changsha, Hunan, 410011, China.
FAU - Xie, Lili
AU  - Xie L
AD  - Department of Ophthalmology, The 2nd Xiangya Hospital, Central South University, 
      Changsha, Hunan, 410011, China; Hunan Clinical Research Center of Ophthalmic 
      Disease, Changsha, Hunan, 410011, China.
FAU - Wang, Xiaoling
AU  - Wang X
AD  - Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, 430060, 
      China.
FAU - Zhang, Lusi
AU  - Zhang L
AD  - Department of Ophthalmology, The 2nd Xiangya Hospital, Central South University, 
      Changsha, Hunan, 410011, China; Hunan Clinical Research Center of Ophthalmic 
      Disease, Changsha, Hunan, 410011, China.
FAU - Chen, Changzheng
AU  - Chen C
AD  - Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, 430060, 
      China.
FAU - Jiang, Bing
AU  - Jiang B
AD  - Department of Ophthalmology, The 2nd Xiangya Hospital, Central South University, 
      Changsha, Hunan, 410011, China; Hunan Clinical Research Center of Ophthalmic 
      Disease, Changsha, Hunan, 410011, China. Electronic address: drjiangb@csu.edu.cn.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190613
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - 0 (Biomarkers)
SB  - IM
MH  - Animals
MH  - Axons/*physiology
MH  - Biomarkers/metabolism
MH  - Blotting, Western
MH  - Cell Survival/physiology
MH  - Cells, Cultured
MH  - Evoked Potentials, Visual/physiology
MH  - Fetal Blood/cytology
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*physiology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Nerve Regeneration/*physiology
MH  - Optic Nerve Injuries/*metabolism
MH  - Photic Stimulation
MH  - Retinal Ganglion Cells/*physiology
MH  - Spheroids, Cellular/cytology
OTO - NOTNLM
OT  - Human umbilical cord blood-derived mesenchymal stem cells
OT  - Neuroprotection
OT  - Optic nerve crush
OT  - Retinal ganglion cells
OT  - Spheroid
OT  - Two-dimensional
EDAT- 2019/06/17 06:00
MHDA- 2020/02/15 06:00
CRDT- 2019/06/17 06:00
PHST- 2018/12/21 00:00 [received]
PHST- 2019/05/09 00:00 [revised]
PHST- 2019/06/12 00:00 [accepted]
PHST- 2019/06/17 06:00 [pubmed]
PHST- 2020/02/15 06:00 [medline]
PHST- 2019/06/17 06:00 [entrez]
AID - S0014-4835(18)30929-1 [pii]
AID - 10.1016/j.exer.2019.107699 [doi]
PST - ppublish
SO  - Exp Eye Res. 2019 Aug;185:107699. doi: 10.1016/j.exer.2019.107699. Epub 2019 Jun 
      13.